Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA

RNAi technology is taking strong position among the key therapeutic modalities, with dozens of siRNA-based programs entering and successfully progressing through clinical stages of drug development. To further explore potentials of RNAi technology as therapeutics, we engineered and tested VEGFR2 siR...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Liu, Xiaoxia, Wang, Wei, Samarsky, Dmitry, Liu, Li, Xu, Qian, Zhang, Wenqing, Zhu, Guangzu, Wu, Ping, Zuo, Xialin, Deng, Houliang, Zhang, Jingjing, Wu, Zhuomin, Chen, Xiaohui, Zhao, Lingfeng, Qiu, Zhiyong, Zhang, Zhongyi, Zeng, Qiyi, Yang, Wei, Zhang, Biliang, Ji, Aimin
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2014
Soggetti:
RNA
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4191406/
https://ncbi.nlm.nih.gov/pubmed/25223783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nar/gku831
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi